NAGE Niagen Bioscience, Inc.

bullish track record → $4.87 +0.03 (+0.6%)
Get emailed when NAGE changes direction
Mkt Cap $390M P/E 24.3 fwd 15.2 52wk $4.16 - $14.69 Earnings 2026-05-06 47d ago
Insider selling: $38,417,174 sold by 7 insiders (30d)
Factor divergence: DIVERGENCE: estimate_revisions, analyst_revisions bullish vs options_sentiment bearish
Est. revisions: +9.1% (1 up, 0 down in 30d)
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net +2.1)

Factor Model

net +2.1 4.0 / 10
Est. Revisions
+0.5
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
+1.0
Narrative Gap
+0.0

Niagen crushes 2025: +30% sales, +106% profit, raises 2026 guide

Watch: Monitor Q1 2026 results and any acceleration in consumer adoption of NAD+ products—the $145 million guidance assumes steady-state execution, but category tailwinds could unlock faster growth. Watch for gross margin trends and whether the company can sustain operating leverage as it scales.

Niagen Bioscience delivered record 2025 results with full-year net sales of $129.4 million (up 30% YoY) and net income of $17.7 million—roughly double 2024's $8.6 million. The company hit the upper end of its original guidance while maintaining a fortress balance sheet: $64.8 million in cash and zero debt. Management guided 2026 revenue to $145 million, implying 15% growth and setting up another year of expansion in the NAD+ supplement market.

Niagen's combination of 106% net income growth on 30% revenue growth signals strong operational leverage and margin expansion. The clean balance sheet and debt-free status give management flexibility to invest in the NAD+ category at a critical growth inflection point, while the conservative 2026 guidance (15% growth vs. prior 30%) suggests room for upside.

Evidence

8d ago Insider buy by CHAU HOI SHUEN SOLINA HOLLY (NAGE): $38,105,108
8d ago Insider sell by LI KA SHING (NAGE): $38,105,108
8d ago Insider buy by PAMIR OZAN (NAGE): $21,397
8d ago Insider buy by LOPEZ CARLOS LUIS (NAGE): $2,146
8d ago Insider buy by PAMIR OZAN (NAGE): $45,616
17d ago Canaccord Lowers Niagen Bioscience, Inc. (NAGE) PT on Updated Forecasts Following Q4 Results yahoo-finance
47d ago XP Inc. (XP) Has Gained Roughly 10% Since FQ4 2025, Here’s What You Should Know yahoo-finance
Fundamentals & Data ▾
Niagen Bioscience, Inc. Healthcare · Biotechnology
Mkt Cap
$390M
P/E
24.3 fwd 15.2
Beta
2.23
52w Range
$4.16 - $14.69
Short Interest
5.5M 10.36%
Days to Cover
3.3 -15%
Technicals downtrend
from 52w Hi
0.0%
1w return
+5.6%
Insiders
buying 4B / 3S
EPS Estimate
$0.06 +9.1% 30d 1up / 0dn
Est. Dispersion
0% 1 analysts
Analyst Target
$14 $12 - $18
Options P/C
1.65
Insider Cluster
strong buy 3B / 3S (officer)
Fund Convergence
strong Renaissance, Citadel, Two Sigma
Financials
Revenue
$34M +16% YoY
Gross Margin
64%
Op Margin
6%
Momentum: decelerating
Top Holders
Renaissance $6M
Citadel $3M
Two Sigma
Recent Filings & Data
insider trade 10
net selling · $38,417,174 sold · $38,174,267 bought
7 insiders · 10 transactions (30d)
Recent transactions
PAMIR OZAN · buy · $45,616
FRIED ROBERT N. · exercise · $220,001
LOPEZ CARLOS LUIS · buy · $2,146
JAKSCH FRANK LOUIS JR · sell · $229,956
JAKSCH FRANK LOUIS JR · exercise · $183,004
PAMIR OZAN · buy · $21,397
PATRICK KRISTIN · sell · $82,110
PATRICK KRISTIN · exercise · $38,320
LI KA SHING · sell · $38,105,108
CHAU HOI SHUEN SOLINA HOLLY · buy · $38,105,108
7 signals · latest 8d ago

Get alerted when NAGE changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.

All stocks → Our calls → How it works →